General Information of Drug (ID: DMACRHS)

Drug Name
4-Benzenesulfonyl-1-(3-phenyl-propyl)-piperidine Drug Info
Synonyms CHEMBL148565; 4-Benzenesulfonyl-1-(3-phenyl-propyl)-piperidine; BDBM50108708; ZINC13472074; 4-(Phenylsulfonyl)-1-hydrocinnamylpiperidine
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
10871642
TTD Drug ID
DMACRHS

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
VESNARINONE DMBKX3C Cardiac failure BD10-BD13 Approved [2]
M100907 DM7ZFBA Sleep-wake disorder 7A00-7B2Z Phase 3 [3]
HP-184 DMNOMV2 Multiple sclerosis 8A40 Phase 2 [4]
NITD609 DMQHBSX Malaria 1F40-1F45 Phase 2 [5]
ABT-229 DMN3S1B Pain MG30-MG3Z Phase 2 [6]
ISOQUINE DMR17YI Malaria 1F40-1F45 Phase 1 [7]
Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1 DMC8935 N. A. N. A. Patented [8]
Isoindoline derivative 5 DMIUTQW N. A. N. A. Patented [9]
Isoindoline derivative 3 DM2MYL9 N. A. N. A. Patented [9]
Isoindoline derivative 4 DMP1NKI N. A. N. A. Patented [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated potassium channel Kv11.1 (KCNH2) TTQ6VDM KCNH2_HUMAN Inhibitor [1]

References

1 4-(Phenylsulfonyl)piperidines: novel, selective, and bioavailable 5-HT(2A) receptor antagonists. J Med Chem. 2002 Jan 17;45(2):492-503.
2 Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorg Med Chem Lett. 2003 Aug 18;13(16):2773-5.
3 Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
4 Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80.
5 Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
6 9-Dihydroerythromycin ethers as motilin agonists--developing structure-activity relationships for potency and safety. Bioorg Med Chem. 2010 Nov 1;18(21):7651-8.
7 Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for ... J Med Chem. 2009 Mar 12;52(5):1408-15.
8 Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
9 The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.